Tiziana Life Sciences shares are trading higher after the company announced the signing of a a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating a combination of the proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone.